Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-03-16 5:41 pm Purchase | 2023-03-14 | 13D | Larimar Therapeutics, Inc. LRMR | James E. Flynn | 16,973,635 39.200% | 10,606 (+0.06%) | Filing History |
| 2023-02-14 2:30 pm Purchase | 2022-09-16 | 13G | Larimar Therapeutics, Inc. LRMR | Perceptive Advisors LLC | 2,860,000 6.600% | 2,860,000 (New Position) | Filing History |
| 2023-02-13 12:04 pm Purchase | 2022-12-31 | 13G | Larimar Therapeutics, Inc. LRMR | CHI Advisors LLC | 3,473,366 8.030% | 1,958,218 (+129.24%) | Filing History |
| 2023-01-20 7:09 pm Purchase | 2022-12-31 | 13G | Larimar Therapeutics, Inc. LRMR | Opaleye Management Inc. | 1,560,000 3.610% | 616,298 (+65.31%) | Filing History |
| 2022-11-14 4:43 pm Sale | 2022-11-14 | 13G | Larimar Therapeutics, Inc. LRMR | RA Capital Management, L.P. | 0 0.000% | -1,334,610 (Position Closed) | Filing History |
| 2022-09-16 5:19 pm Purchase | 2022-09-16 | 13D | Larimar Therapeutics, Inc. LRMR | James E. Flynn | 16,963,029 42.450% | 11,126,786 (+190.65%) | Filing History |
| 2022-02-18 4:32 pm Purchase | 2022-02-15 | 13G | Larimar Therapeutics, Inc. LRMR | Opaleye Management Inc. | 943,702 5.320% | 943,702 (New Position) | Filing History |
| 2022-02-15 2:43 pm Sale | 2021-12-31 | 13G | Larimar Therapeutics, Inc. LRMR | ACUTA CAPITAL PARTNERS LLC | 0 0.000% | -863,100 (Position Closed) | Filing History |
| 2022-02-14 4:11 pm Sale | 2021-12-31 | 13G | Larimar Therapeutics, Inc. LRMR | RA Capital Management, L.P. | 1,334,610 7.500% | -180,541 (-11.92%) | Filing History |
| 2022-02-11 5:27 pm Sale | 2021-12-31 | 13G | Larimar Therapeutics, Inc. LRMR | Vivo Capital IX, LLC | 326,888 1.800% | -326,891 (-50.00%) | Filing History |
| 2022-02-11 4:29 pm Sale | 2021-12-31 | 13G | Larimar Therapeutics, Inc. LRMR | ORBIMED ADVISORS LLC | 0 0.000% | -732,323 (Position Closed) | Filing History |
| 2022-02-11 11:34 am Unchanged | 2021-12-31 | 13G | Larimar Therapeutics, Inc. LRMR | CHI Advisors LLC | 1,515,148 8.560% | 0 (Unchanged) | Filing History |
| 2021-07-02 5:08 pm Purchase | 2021-06-30 | 13D | Larimar Therapeutics, Inc. LRMR | James E. Flynn | 5,836,243 32.940% | 686,171 (+13.32%) | Filing History |
| 2021-05-26 1:48 pm Unchanged | 2021-05-25 | 13D | Larimar Therapeutics, Inc. LRMR | James E. Flynn | 5,150,072 33.500% | 0 (Unchanged) | Filing History |
| 2021-05-21 5:05 pm Purchase | 2021-05-21 | 13D | Larimar Therapeutics, Inc. LRMR | James E. Flynn | 5,150,072 33.500% | 5,533 (+0.11%) | Filing History |
| 2021-03-02 1:58 pm Purchase | 2020-12-31 | 13G | Larimar Therapeutics, Inc. LRMR | CHI Advisors LLC | 1,515,148 9.900% | 1,515,148 (New Position) | Filing History |
| 2021-02-16 4:47 pm Purchase | 2021-02-04 | 13G | Larimar Therapeutics, Inc. LRMR | Logos Global Master Fund LP | 300,000 2.000% | 300,000 (New Position) | Filing History |
| 2021-02-16 4:39 pm Purchase | 2020-12-31 | 13G | Larimar Therapeutics, Inc. LRMR | RA Capital Management, L.P. | 1,515,151 9.900% | 1,515,151 (New Position) | Filing History |
| 2021-02-16 3:11 pm Purchase | 2020-12-31 | 13G | Larimar Therapeutics, Inc. LRMR | 683 Capital Management LLC | 220,136 1.400% | 220,136 (New Position) | Filing History |
| 2021-02-16 1:03 pm Purchase | 2020-12-31 | 13G | Larimar Therapeutics, Inc. LRMR | Sio Capital Management LLC | 188,661 1.230% | 188,661 (New Position) | Filing History |